Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation (ROXI-EVEREST)
A Phase 3, Randomized, Multicenter, Double-blind Study to Assess Stroke and Systemic Embolism Prevention With REGN7508, a Monoclonal Antibody Against Factor XI, Versus Apixaban in Participants With Atrial Fibrillation (ROXI-EVEREST)
This study is researching an experimental drug called REGN7508 (called "study drug") and how it compares against another treatment called apixaban. The study is focused on people who have atrial fibrillation, which means that the heart beats too fast and unevenly.
The aim of the study is to see how safe and effective REGN7508 is in preventing stroke and/or systemic embolism in participants with atrial fibrillation and how it compares against participants that will receive apixaban in this study.
The study is looking at several other research questions, including:
- What side effects may happen from taking the study drug
- Whether the body makes antibodies against the study drug (which could make the study drug less effective or could lead to side effects)
Panoramica dello studio
Stato
Stato
Condizioni
Condizioni
Intervento / Trattamento
Intervento / Trattamento
Tipo di studio
Tipo di studio
Iscrizione (Stimato)
Iscrizione
Fase
Fase
- Fase 3
Contatti e Sedi
Contatto studio
Contatto studio
- Nome: Clinical Trials Administrator
- Numero di telefono: 844-734-6643
- Email: clinicaltrials@regeneron.com
Luoghi di studio
-
-
-
Longueuil, Canada, J4H4B9
- Reclutamento
- Viacar Recherches Cliniques inc.
-
-
Ontario
-
Hamilton, Ontario, Canada, L8L 5G4
- Reclutamento
- Premiere Clinical Trial Network
-
Scarborough Village, Ontario, Canada, M1B 4Z8
- Reclutamento
- Heart Health Institute Research Inc.
-
-
Quebec
-
Sherbrooke, Quebec, Canada, J1LOK3
- Reclutamento
- Diex Recherche Inc.
-
-
-
-
Aichi-ken
-
Nagoya, Aichi-ken, Giappone, 466-8650
- Reclutamento
- Japanese Red Cross Aichi Medical Center Nagoya Daini Hospital
-
-
Ehime
-
Uwajima, Ehime, Giappone, 798-8510
- Reclutamento
- Uwajima City Hospital
-
-
Fukuoka
-
Onga District, Fukuoka, Giappone, 811-4342
- Reclutamento
- Onga Nakama Medical Association Onga Hospital
-
-
Gifu
-
Gifu, Gifu, Giappone, 500-8717
- Reclutamento
- Gifu Prefectural General Medical Center - Main Hospital Building
-
-
Hokkaido
-
Sapporo, Hokkaido, Giappone, 062-0003
- Reclutamento
- Hanaoka Seishu Memorial Hospital
-
-
Hyōgo
-
Kawanishi, Hyōgo, Giappone, 666-0125
- Reclutamento
- The Veritas Hospital
-
-
Ibaraki
-
Higashiibaraki District, Ibaraki, Giappone, 311-3193
- Reclutamento
- National Hospital Organization Mito Medical Center
-
Tsuchiura, Ibaraki, Giappone, 300-8585
- Reclutamento
- National Hospital Organization Kasumigaura Medical Center
-
-
Kanagawa
-
Yokohama, Kanagawa, Giappone, 234-0054
- Reclutamento
- Saiseikai Yokohama-shi Nanbu Hospital
-
-
Kyoto
-
Kyoto, Kyoto, Giappone, 607-8062
- Reclutamento
- Rakuwakai Otowa Hospital
-
-
Shizuoka
-
Shizuoka, Shizuoka, Giappone, 420-8630
- Reclutamento
- Shizuoka City Shizuoka Hospital, East Building
-
-
Tokyo
-
Hachiōji, Tokyo, Giappone, 192-0918
- Reclutamento
- Minamino Cardiovascular Hospital
-
Suginami Ward, Tokyo, Giappone, 168-0065
- Reclutamento
- NewHeart Watanabe International Hospital
-
-
Yokohama-shi
-
Kanagawa, Yokohama-shi, Giappone, 247-0005
- Reclutamento
- JA Tsuchiura Kyodo General Hospital
-
-
-
-
Alabama
-
Alexander City, Alabama, Stati Uniti, 35010
- Reclutamento
- Advanced Cardiovascular
-
Dothan, Alabama, Stati Uniti, 36305
- Reclutamento
- SEC Clinical Research
-
Fairhope, Alabama, Stati Uniti, 36532
- Reclutamento
- Eastern Shore Research Institute
-
-
Arizona
-
Glendale, Arizona, Stati Uniti, 85306
- Reclutamento
- West Valley Clinical Trials
-
Scottsdale, Arizona, Stati Uniti, 85260
- Reclutamento
- Scottsdale Clinical Trials
-
-
Arkansas
-
Little Rock, Arkansas, Stati Uniti, 72205
- Reclutamento
- Arkansas Cardiology P.A.
-
-
California
-
Covina, California, Stati Uniti, 91723
- Reclutamento
- Valley Clinical Trials, Inc
-
Fremont, California, Stati Uniti, 94538
- Reclutamento
- Mission Cardiovascular Research Institute
-
Huntington Beach, California, Stati Uniti, 92648
- Reclutamento
- National Institute of California Heart and Vein Specialists
-
Inglewood, California, Stati Uniti, 90301
- Reclutamento
- Alliance Clinical Los Angeles
-
La Jolla, California, Stati Uniti, 92037
- Reclutamento
- Profound Research LLC at San Diego Cardiovascular Associates
-
Newport Beach, California, Stati Uniti, 92663
- Reclutamento
- Radin Cardiovascular Medical Group
-
Northridge, California, Stati Uniti, 91325
- Reclutamento
- Valley Clinical Trials, LLC dba Flourish Research
-
Pasadena, California, Stati Uniti, 91105
- Reclutamento
- Southern California Heart Specialists
-
Redding, California, Stati Uniti, 96001
- Reclutamento
- The Cardiovascular Center
-
Santa Maria, California, Stati Uniti, 93454
- Reclutamento
- FOMAT - Comprehensive Cardiovascular Care
-
Ventura, California, Stati Uniti, 93003
- Reclutamento
- Cardiology Associates Medical Group
-
West Hills, California, Stati Uniti, 91307
- Reclutamento
- Interventional Cardiology Medical Group
-
-
Florida
-
Boca Raton, Florida, Stati Uniti, 33434
- Reclutamento
- Excel Medical Clinical Trials, dba Flourish Research
-
Cutler Bay, Florida, Stati Uniti, 33189
- Reclutamento
- Nouvelle Clinical Research LLC
-
Inverness, Florida, Stati Uniti, 34452
- Reclutamento
- Nature Coast Clinical Research - Inverness
-
Jacksonville, Florida, Stati Uniti, 32216
- Reclutamento
- East Coast Institute for Research, Jacksonville
-
Medley, Florida, Stati Uniti, 33166
- Reclutamento
- South Florida Research Organization LLC
-
Miami, Florida, Stati Uniti, 33135
- Reclutamento
- Novera Clinical Research
-
New Smyrna Beach, Florida, Stati Uniti, 32168
- Reclutamento
- Healix Clinical Research
-
Pensacola, Florida, Stati Uniti, 32503
- Reclutamento
- Sec Clinical Research
-
Saint Augustine, Florida, Stati Uniti, 32086
- Reclutamento
- Flourish Research, St. Johns Center for Clinical Research
-
Saint Augustine, Florida, Stati Uniti, 32086
- Reclutamento
- East Coast Institute for Research, St. Augustine
-
Sarasota, Florida, Stati Uniti, 34239
- Reclutamento
- Cardiovascular Center of Sarasota Foundation for Research and Education
-
Winter Park, Florida, Stati Uniti, 32789
- Reclutamento
- Clinical Site Partners, LLC DBA Flourish Research
-
-
Georgia
-
Atlanta, Georgia, Stati Uniti, 30342
- Reclutamento
- Atlanta Clinical Research Centers
-
Atlanta, Georgia, Stati Uniti, 30310
- Reclutamento
- Morehouse School Of Medicine
-
Johns Creek, Georgia, Stati Uniti, 30024
- Reclutamento
- NSC Research, Inc
-
-
Indiana
-
Hobart, Indiana, Stati Uniti, 46342
- Reclutamento
- Profound Research, Advanced Cardiovascular Care + Electrophysiology Clinic
-
Indianapolis, Indiana, Stati Uniti, 46237
- Reclutamento
- Franciscan Physician Network, Indiana Heart Physicians
-
Munster, Indiana, Stati Uniti, 46321
- Reclutamento
- Profound Research, Powers Health Medical Group - Electrophysiology
-
Munster, Indiana, Stati Uniti, 46321-4054
- Reclutamento
- Cardiovascular Research of Northwest Indiana, LLC
-
-
Louisiana
-
West Monroe, Louisiana, Stati Uniti, 71291
- Reclutamento
- Monroe Research, LLC
-
-
Maryland
-
Ft. Washington, Maryland, Stati Uniti, 20744
- Reclutamento
- Anderson Medical Research
-
-
Massachusetts
-
Foxborough, Massachusetts, Stati Uniti, 02035
- Reclutamento
- K2 Medical Research, Foxboro
-
-
Michigan
-
Bloomfield Hills, Michigan, Stati Uniti, 48304
- Reclutamento
- Profound Research, Cardiology and Vascular Associates (CAVA) - Bloomfield Hills
-
Farmington Hills, Michigan, Stati Uniti, 48334
- Reclutamento
- Profound Research, Millennium Cardiology
-
Flint, Michigan, Stati Uniti, 48503
- Reclutamento
- Flint Clinical Research
-
Flint, Michigan, Stati Uniti, 48504
- Reclutamento
- AA Medical Research Center (MRC)
-
-
New York
-
Staten Island, New York, Stati Uniti, 10309
- Reclutamento
- Super Health Pharmacy
-
-
North Carolina
-
Concord, North Carolina, Stati Uniti, 28025
- Reclutamento
- Hawthorne Health, Moose Pharmacy of Concord
-
High Point, North Carolina, Stati Uniti, 27260
- Reclutamento
- Peters Medical Research
-
-
North Dakota
-
Fargo, North Dakota, Stati Uniti, 58104
- Reclutamento
- Lillestol Research LLC
-
-
Ohio
-
Marion, Ohio, Stati Uniti, 43302
- Reclutamento
- K&R Research LLC
-
Maumee, Ohio, Stati Uniti, 43537
- Reclutamento
- Advanced Medical Research
-
-
South Dakota
-
Rapid City, South Dakota, Stati Uniti, 57701
- Reclutamento
- Monument Health Clinical Research
-
-
Tennessee
-
Knoxville, Tennessee, Stati Uniti, 37912
- Reclutamento
- Norwood Family Medicine
-
Tullahoma, Tennessee, Stati Uniti, 37388
- Reclutamento
- Tennessee Center for Clinical Trials
-
-
Texas
-
Amarillo, Texas, Stati Uniti, 79106
- Reclutamento
- PharmaTex Research
-
Brownsville, Texas, Stati Uniti, 78520
- Reclutamento
- PanAmerican Clinical Research
-
Houston, Texas, Stati Uniti, 77061
- Reclutamento
- Synergy Groups Medical
-
Houston, Texas, Stati Uniti, 77094
- Reclutamento
- West Houston Area Clinical Trial Consultants, LLC
-
Houston, Texas, Stati Uniti, 77036
- Reclutamento
- Synergy Group Medical
-
McKinney, Texas, Stati Uniti, 75071
- Reclutamento
- Texas Institute of Cardiology PA
-
Missouri City, Texas, Stati Uniti, 77459
- Reclutamento
- Synergy Group Medical, LLC
-
Odessa, Texas, Stati Uniti, 79761
- Reclutamento
- Permian Research Foundation
-
Tyler, Texas, Stati Uniti, 75701
- Reclutamento
- Tyler Cardiovascular Consultants
-
-
Utah
-
Clinton, Utah, Stati Uniti, 84015
- Reclutamento
- Alpine Research TC
-
Provo, Utah, Stati Uniti, 84604
- Reclutamento
- Boeson Research PVU
-
-
Virginia
-
Manassas, Virginia, Stati Uniti, 20109
- Reclutamento
- Carient Heart & Vascular
-
Vienna, Virginia, Stati Uniti, 22182
- Reclutamento
- Conquest Research
-
-
Criteri di partecipazione
Criteri di ammissibilità
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Key Inclusion Criteria:
-
Has AF or flutter (paroxysmal or persistent), not considered to be secondary to a reversible cause, and an indication for indefinite anticoagulation treatment as described in the protocol
-
Meets one of the following:
- CHA2DS2-VA [C: Congestive heart failure; H: Hypertension; A2: Age ≥75 years (double points); D: Diabetes mellitus; S2: Stroke or TIA or Systemic embolism (double points); V: Vascular disease; A: Age 65-74 years] score ≥2 and Oral Anticoagulant (OAC) naïve OR
- CHA2DS2-VA score ≥3 OR
- CHA2DS2-VA score of 2 AND at least 1 enrichment criteria as described in the protocol
-
Must have an International Normalized Ratio (INR) <2.5 at the time of randomization if taking warfarin or another Vitamin K Antagonist (VKA)
Key Exclusion Criteria:
- Has a mechanical heart valve prosthesis (Note: transcatheter aortic valve replacement is not an exclusion)
- Has known moderate-to-severe mitral stenosis
- Has had a successful ablation therapy without documented recurrent AF or a participant after Left Atrial Appendage (LAA) occlusion/exclusion or plan for ablation or LAA occlusion/exclusion within the next 6 months starting from randomization
- Had an ischemic stroke within 2 days prior to randomization
- Has persistent, uncontrolled hypertension (per investigator's discretion)
- Has estimated Glomerular Filtration Rate (eGFR) <15 mL/min/1.73m2 within 30 days prior to randomization or is on dialysis or expected to be started on dialysis within the next 6 months starting from randomization
Note: Other protocol-defined Inclusion/ Exclusion criteria apply
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Prevenzione
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Quadruplicare
Numero di armi
Armi e interventi
Gruppo di partecipanti / ArmGruppo di partecipanti / Arm |
Intervento / TrattamentoIntervento / Trattamento |
|---|---|
|
Sperimentale: REGN7508 + Placebo
|
Administered per the protocol Administered per the protocol
Altri nomi:
|
|
Comparatore attivo: Apixaban + Placebo
|
Administered per the protocol Administered per the protocol |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misure di risultato primarie
Misura del risultato |
Lasso di tempo |
|---|---|
|
Time to first occurrence of stroke (ischemic, hemorrhagic, or of unspecified type) or systemic embolism
Lasso di tempo: Approximately 36 months
|
Approximately 36 months
|
|
Time to first occurrence of International Society on Thrombosis and Haemostasis (ISTH) major bleeding or ISTH Clinically Relevant Non-Major (CRNM) bleeding
Lasso di tempo: Approximately 36 months
|
Approximately 36 months
|
Misure di risultato secondarie
Misure di risultato secondarie
Misura del risultato |
Lasso di tempo |
|---|---|
|
Time to first occurrence of stroke (ischemic, hemorrhagic, or of unspecified type), systemic embolism, ISTH major bleeding, or ISTH CRNM bleeding
Lasso di tempo: Approximately 36 months
|
Approximately 36 months
|
|
Time to first occurrence of stroke (ischemic, hemorrhagic, or of unspecified type), systemic embolism, or ISTH major bleeding
Lasso di tempo: Approximately 36 months
|
Approximately 36 months
|
|
Time to first occurrence of stroke (ischemic, hemorrhagic, or of unspecified type), systemic embolism, ISTH major bleeding, or all-cause death
Lasso di tempo: Approximately 36 months
|
Approximately 36 months
|
|
Time to first occurrence of ISTH major bleeding
Lasso di tempo: Approximately 36 months
|
Approximately 36 months
|
|
Time to first occurrence of hemorrhagic stroke, intracerebral hemorrhage, or hemorrhagic transformation of an ischemic stroke
Lasso di tempo: Approximately 36 months
|
Approximately 36 months
|
|
Time to occurrence of fatal bleeding
Lasso di tempo: Approximately 36 months
|
Approximately 36 months
|
|
Number of ISTH major bleeding events
Lasso di tempo: Approximately 36 months
|
Approximately 36 months
|
|
Number of ISTH CRNM bleeding events
Lasso di tempo: Approximately 36 months
|
Approximately 36 months
|
|
Number of minor bleeding events
Lasso di tempo: Approximately 36 months
|
Approximately 36 months
|
|
Time to all-cause death
Lasso di tempo: Approximately 36 months
|
Approximately 36 months
|
|
Occurrence of Treatment-Emergent Adverse Events (TEAEs)
Lasso di tempo: Approximately 39 months
|
Approximately 39 months
|
|
Severity of TEAEs
Lasso di tempo: Approximately 39 months
|
Approximately 39 months
|
|
Occurrence of Anti-Drug Antibodies (ADA) to REGN7508
Lasso di tempo: Approximately 36 months
|
Approximately 36 months
|
|
Magnitude of ADA to REGN7508
Lasso di tempo: Approximately 36 months
|
Approximately 36 months
|
Collaboratori e investigatori
Sponsor
Sponsor
Investigatori
Investigatori
- Direttore dello studio: Clinical Trial Management, Regeneron Pharmaceuticals
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Inizio studio
Completamento primario (Stimato)
Completamento primario
Completamento dello studio (Stimato)
Completamento dello studio
Date di iscrizione allo studio
Primo inviato
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Primo Inserito
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento pubblicato
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
- Disturbi cerebrovascolari
- Malattie del cervello
- Malattie del sistema nervoso centrale
- Malattie del sistema nervoso
- Malattie vascolari
- Malattia cardiovascolare
- Processi patologici
- Malattie cardiache
- Aritmie, cardiache
- Embolia e Trombosi
- Condizioni patologiche, segni e sintomi
- Ictus
- Trombosi
- Fibrillazione atriale
- Emorragia
- apixaban
Altri numeri di identificazione dello studio
Altri numeri di identificazione dello studio
- R7508-CVA-24114
- 2025-521617-97-00 (Ctis)
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Descrizione del piano IPD
All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing
Periodo di condivisione IPD
When Regeneron has:
- received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication or has globally discontinued development of the product for all indications on or after April 2020 and has no plans for future development
- made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry)
- the legal authority to share the data, and
- ensured the ability to protect participant privacy
Criteri di accesso alla condivisione IPD
Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf
Tipo di informazioni di supporto alla condivisione IPD
- STUDIO_PROTOCOLLO
- LINFA
- ICF
- CODICE_ANALITICO
- RSI
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .